Germline TP53 noncoding variant (rs78378222) prevalence in cohorts of prostatic adenocarcinoma and benign prostatic hyperplasia: further evidence from southern Brazil and novel insights into its functional impact mediated by the circRNAs-miRNAs-TP53 regulatory axis

Every cell in the human body carries a set of instructions, a genetic blueprint that dictates how it grows, divides, and eventually dies. Among these instructions is a critical section known as the TP53 gene, often described as the body's master guardian. Its job is to monitor the health of the cell; if the DNA becomes damaged, this gene orders the cell to stop dividing or to self-destruct, preventing the formation of tumors. While scientists have long known that errors in the main coding part of this gene can lead to cancer, they are only beginning to understand the subtle instructions found in the non-coding regions that sit at the very end of the genetic message. These tail-end sections do not build proteins themselves, but they act like volume knobs and switches, controlling how much of the protective protein is actually produced and how long it lasts. One specific change in this tail end has been linked to a higher risk of various cancers in European populations, but its behavior in other parts of the world, and its role in conditions that are not yet cancer, remains a mystery.

Researchers in southern Brazil set out to investigate this specific genetic variation in a large group of men, looking at both those with prostate cancer and those with a common, non-cancerous enlargement of the prostate. They focused on a tiny alteration in the DNA sequence that changes how the cell reads the final instructions for the guardian protein. By examining blood samples from 320 men, the team found that this specific genetic change is quite rare in their local population. It appeared in only one man with prostate cancer and one man with the benign condition, representing a frequency of less than one percent in both groups. This is notably lower than what has been observed in European studies, suggesting that the genetic makeup of the population plays a significant role in how common this risk factor is. The findings confirm that while this variation exists in Brazil, it is not a widespread driver of prostate issues in the same way it might be elsewhere.

Beyond simply counting how many people carried the gene, the study ventured into a new area of biological research to understand how this variation might work. The scientists explored a complex network involving tiny molecules called microRNAs, which act like dimmer switches to lower the production of the guardian protein, and circular RNAs, which are ring-shaped molecules that can soak up these switches and prevent them from working. The researchers used computer models to map out which circular molecules might interact with the specific microRNAs affected by this genetic change. Their analysis revealed that while many such interactions exist in the human body, two specific circular molecules were significantly more active in the cancerous prostate tissues compared to the benign ones. These two molecules, derived from genes named ARID1B and NR3C1, were found to be turned up in the cancer samples, suggesting they might be part of the machinery that allows the cancer to grow when the genetic switch is flipped.

The study also looked at how this genetic change might travel through families alongside other genetic variations. In populations of European descent, this specific change is often inherited together with another rare variation in a different part of the same gene, a pattern that was not observed in the same way in other groups. This suggests that the history of a population's ancestry shapes how these genetic risks are passed down. The researchers concluded that while their findings in Brazil are limited by the small number of people carrying the gene, the work provides a crucial first look at how this variation behaves in non-cancerous prostate tissue. Most importantly, they have opened a new door for understanding the indirect ways cells regulate their most important safety mechanisms. By highlighting the potential role of these circular molecules, the study offers a fresh perspective for future experiments, inviting scientists to test whether these specific ring-shaped molecules are indeed the missing link in how this genetic change influences the development of prostate disease.